DU
HARP

Delphia (USA)’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Delphia (USA)’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,151
Closed -$57K – 519
2022
Q1 		$57K Buy
+1,151
New +$59.7K 0.04% 318

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Delphia (USA)'s HARP Position: Q2 2022 in Review

Delphia (USA) sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 1,151 shares — an estimated $57K sold.

Delphia (USA) first reported a position in HARP in Q1 2022 and held it in 1 quarter. The position peaked at $57K in Q1 2022. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • Delphia (USA) reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Delphia (USA) sold 1,151 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $57K.
  • Delphia (USA) first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Delphia (USA)'s Harpoon Therapeutics, Inc. Common Stock position peaked at $57K in Q1 2022.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Delphia (USA)'s 13F filing for Q2 2022, filed 15 Aug 2022.